Proteome Sciences PLC Total Liabilities
Proteome Sciences PLC total liabilities. Based on the latest financial reports, Proteome Sciences PLC (PRM) has total liabilities worth GBX17.79 Million GBX (≈ $2.16K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Proteome Sciences PLC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Proteome Sciences PLC (1994–2025)
Total liabilities of Proteome Sciences PLC from 1994 to 2025. This chart illustrates how Proteome Sciences PLC's total liabilities have evolved over time, based on quarterly financial data.
Proteome Sciences PLC Competitors by Total Liabilities
The table below lists competitors of Proteome Sciences PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digitalbox PLC
LSE:DBOX
|
UK | GBX366.00K |
|
Serinus Energy
LSE:SENX
|
UK | GBX50.04 Million |
|
Fadel Partners Inc
LSE:FADL
|
UK | GBX6.56 Million |
|
Bumrungrad Hospital Public Company Limited
F:BZ7A
|
Germany | €5.45 Billion |
|
Trafalgar New Homes Plc
LSE:TRAF
|
UK | GBX4.53 Million |
|
Harmony Energy Income Trust PLC
LSE:HEIT
|
UK | GBX373.69K |
|
Bisichi Mining PLC
LSE:BISI
|
UK | GBX22.12 Million |
Liability Composition Analysis (1994–2025)
This chart breaks down Proteome Sciences PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Proteome Sciences PLC.
Liquidity & Leverage Metrics
Proteome Sciences PLC Total Liabilities Ratios Explained
Proteome Sciences PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Proteome Sciences PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Proteome Sciences PLC (1994–2025)
The table below shows the annual total liabilities of Proteome Sciences PLC from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX17.79 Million ≈ $2.16K |
+13.12% |
| 2024-12-31 | GBX15.72 Million ≈ $1.91K |
+8.26% |
| 2023-12-31 | GBX14.52 Million ≈ $1.77K |
-100.00% |
| 2022-12-31 | GBX1.44 Trillion ≈ $175.75 Million |
+9.91% |
| 2021-12-31 | GBX1.31 Trillion ≈ $159.91 Million |
+2.46% |
| 2020-12-31 | GBX1.28 Trillion ≈ $156.06 Million |
+19.36% |
| 2019-12-31 | GBX1.07 Trillion ≈ $130.74 Million |
+0.47% |
| 2018-12-31 | GBX1.07 Trillion ≈ $130.13 Million |
+0.21% |
| 2017-12-31 | GBX1.07 Trillion ≈ $129.85 Million |
+796.27% |
| 2016-12-31 | GBX119.08 Billion ≈ $14.49 Million |
-88.70% |
| 2015-12-31 | GBX1.05 Trillion ≈ $128.26 Million |
-18.41% |
| 2014-12-31 | GBX1.29 Trillion ≈ $157.19 Million |
+0.96% |
| 2013-12-31 | GBX1.28 Trillion ≈ $155.70 Million |
+16583717.49% |
| 2012-12-31 | GBX7.72 Million ≈ $938.87 |
+1.40% |
| 2011-12-31 | GBX7.61 Million ≈ $925.92 |
-9.17% |
| 2010-12-31 | GBX8.38 Million ≈ $1.02K |
-45.73% |
| 2009-12-31 | GBX15.44 Million ≈ $1.88K |
+27.95% |
| 2008-12-31 | GBX12.07 Million ≈ $1.47K |
+37.14% |
| 2007-12-31 | GBX8.80 Million ≈ $1.07K |
+131.04% |
| 2006-12-31 | GBX3.81 Million ≈ $463.32 |
+120.88% |
| 2005-12-31 | GBX1.72 Million ≈ $209.76 |
+12.03% |
| 2004-12-31 | GBX1.54 Million ≈ $187.24 |
-40.43% |
| 2003-12-31 | GBX2.58 Million ≈ $314.31 |
+30.20% |
| 2002-12-31 | GBX1.98 Million ≈ $241.41 |
+60.27% |
| 2001-12-31 | GBX1.24 Million ≈ $150.63 |
-21.40% |
| 2000-12-31 | GBX1.57 Million ≈ $191.63 |
+125.97% |
| 1999-12-31 | GBX697.00K ≈ $84.80 |
-19.14% |
| 1998-12-31 | GBX862.00K ≈ $104.88 |
+56.44% |
| 1997-12-31 | GBX551.00K ≈ $67.04 |
+93.33% |
| 1996-12-31 | GBX285.00K ≈ $34.68 |
-40.63% |
| 1995-12-31 | GBX480.00K ≈ $58.40 |
-30.23% |
| 1994-12-31 | GBX688.00K ≈ $83.71 |
0.00% |
| 1994-10-31 | GBX688.00K ≈ $83.71 |
-- |
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more